Clinical Trials Logo

Myelodysplastic Syndromes clinical trials

View clinical trials related to Myelodysplastic Syndromes.

Filter by:

NCT ID: NCT04942730 Completed - Clinical trials for Myelodysplastic Syndromes

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

FluBuBe
Start date: January 21, 2021
Phase: Phase 2
Study type: Interventional

Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure. Different technologies of with replete or depleted graft are associated with 10-20% of graft failures. Fludarabine and busulfan conditioning is the most commonly used approach for a variety of disease. Furthermore combination of fludarabine and bendamustine was sufficient to facilitate engraftment in patients with chronic lymphocytic leukemia and lymphomas. The aim of the study is to evaluate whether addition of bendamustine to fladarabine and busulfan conditioning reduces the risk of primary graft failure after haploidentical allograft.

NCT ID: NCT04926194 Completed - Clinical trials for Myelodysplastic/Myeloproliferative Neoplasm

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm

DSC-SR
Start date: March 11, 2021
Phase: Phase 2
Study type: Interventional

This is a single participant study of decidual stromal cells (DSC) for the treatment of steroid refractory graft-versus-host disease (GVHD) in a patient with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).

NCT ID: NCT04842604 Completed - Clinical trials for Acute Myeloid Leukemia

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Start date: May 17, 2021
Phase: Phase 3
Study type: Interventional

An open-label study available to all eligible participants from Study B1371019 and participants originating from Study B1371012 continuing on study intervention with azacitidine with or without glasdegib.

NCT ID: NCT04752163 Completed - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Start date: March 25, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the effect of DS-1594b with or without azacitidine, venetoclax, or mini-HCVD in treating patients with acute myeloid leukemia or acute lymphoblastic leukemia that has come back (recurrent) or not responded to treatment (refractory). Chemotherapy drugs, such as azacitidine, venetoclax, and mini-HCVD, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. DS-1594b may inhibit specific protein bindings that cause blood cancer. Giving DS-1594b, azacitidine, and venetoclax, or mini-HCVD may work better in treating patients with acute myeloid leukemia or acute lymphoblastic leukemia.

NCT ID: NCT04718844 Completed - Clinical trials for Non-transfusion-dependent Thalassemia

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Start date: April 14, 2021
Phase: Phase 1
Study type: Interventional

This study will investigate the safety and tolerability of SLN124 in patients with Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome (MDS) after single ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts of 56 patients with Thalassaemia and up to 7 cohorts of 56 patients with MDS will be enrolled. Each subject will receive single or multiple doses of SLN124 or placebo given by subcutaneous (s.c) injection.

NCT ID: NCT04712942 Completed - Clinical trials for Myelodysplastic Syndromes

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

MDS/AML with MRD and impending relapse after allogeneic stem cell transplantation and/or conventional chemotherapy

NCT ID: NCT04676945 Completed - Clinical trials for Myelodysplastic Syndromes

Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients

Start date: August 21, 2020
Phase:
Study type: Observational

A comparison of treated vs untreated patients with MDS with a sample size of approximately 8000 patients in 11 countries.

NCT ID: NCT04666025 Completed - Clinical trials for Acute Myeloid Leukemia

SARS-CoV-2 Donor-Recipient Immunity Transfer

Start date: September 23, 2020
Phase:
Study type: Observational

This study investigates whether donors with previous exposure to COVID-19 can pass their immunity by hematopoietic (blood) stem cell transplant (HCT) donation to patients that have not been exposed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes the COVID19 infection. This study may provide critical information for medical decision-making and possible immunotherapy interventions in immunocompromised transplant recipients, who are at high risk for COVID19 severe illness.

NCT ID: NCT04629430 Completed - Multiple Myeloma Clinical Trials

Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT

HCTDiet
Start date: February 19, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to see whether hematopoietic stem cell transplant (HSCT) patients can consistently eat a diet rich in prebiotics. This type of diet may be helpful in maintaining diversity in the gastrointestinal (GI) system and therefore potentially decreasing risk of other GI problems.

NCT ID: NCT04628338 Completed - Clinical trials for Myelodysplastic Syndromes

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Start date: March 8, 2021
Phase: Early Phase 1
Study type: Interventional

This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT with no active or history of III-IV acute graft-versus-host disease (GVHD). It is hypothesized that IFN-γ will promote graft-vs-leukemia (GVL) in patients with AML/MDS that has relapsed after alloSCT.